A CEO sent his stock surging 15% when he likened his new depression drug to an antibiotic — but a consultant to the company told us it won’t work that way (SAGE)
|06/21/2018||Posted by BusinessMediaguide.Com under General World News||
- Investors’ excitement about a promising new drug for depression reached a fever pitch last week when the CEO of the company behind it likened the drug to an antibiotic.
- Sage Therapeutics’ CEO Jeff Jonas said the drug, called SAGE-217, could be administered like a two-week course of antibiotics, which are given only once.
- A once-only course of treatment is essentially unheard of for depression, and experts within and outside of the company say they doubt that’s how SAGE-217 would actually work. Instead, they say it would likely need to be given monthly.
- Sage has yet to complete any long-term studies of the drug.
Investors’ read more >>>